Three cancer drugs separately earned FDA approval: The KRAS inhibitor sotorasib (Lumakras; Amgen) was approved for use with the EGFR inhibitor panitumumab (Vectibix; Amgen) to treat patients with ...

1Combination Strategies for Translational Immunotherapy, Immunology and Immunotherapy Program, Centro de Investigación Médica Aplicada (CIMA) Universidad de Navarra, Pamplona, Spain. 2Department of ...

1Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.

3Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. *Corresponding Author: David A. Reardon, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.

1Northwestern University, Chicago, Illinois.

1Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.

1Division of Solid Tumor Oncology, Memorial Sloan Kettering, New York, New York. *Corresponding Author: Luis A. Diaz Jr, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. E ...

NCI Director W. Kimryn Rathmell, MD, PhD, announced today that she will step down effective Monday, January 20, the same day Donald Trump will be inaugurated as president. Rathmell, who had previously ...

Major Finding: Elevated bile acids (BA) in liver cancer contribute to T-cell dysfunction. Concept: BA accumulation in T cells promotes ER stress, reducing effector function and viability. Impact: ...

Although it has risen from 7% over the past decade, the relative 5-year survival rate for pancreatic cancer is 13%, the same rate as reported last year, according to the just released American Cancer ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

1Department of Biology, University of Rochester, Rochester, New York. Search for other works by this author on: 2Westlake Disease Modeling Lab, Westlake Laboratory of Life Sciences and Biomedicine, ...